Bulletin
Investor Alert

Market Pulse Archives

Aug. 19, 2022, 7:14 p.m. EDT

Novavax COVID-19 vaccine authorized for U.S. teens

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Novavax Inc. (NVAX)
  • X
    Moderna Inc. (MRNA)
  • X
    BioNTech SE ADR (BNTX)

or Cancel Already have a watchlist? Log In

By Jeremy C. Owens

The Food and Drug Administration authorized Novavax Inc.'s /zigman2/quotes/202614340/composite NVAX -3.61% COVID-19 vaccine for use in U.S. teenagers on Friday. Novavax's recombinant protein-based vaccine uses different technology than the mRNA shots developed by Moderna Inc. /zigman2/quotes/205619834/composite MRNA -0.04% and BioNTech SE /zigman2/quotes/214419716/composite BNTX -0.28% , and received an emergency-use authorization by the FDA for adults in July. The vaccine still requires a policy recommendation for use by the Centers for Disease Control, which followed the FDA by about a week when authorizing the Novavax shot for adults. Novavax shares ticked 0.6% higher in late trading Friday, after the announcement; the stock has declined nearly 75% so far this year, as the S&P 500 index /zigman2/quotes/210599714/realtime SPX -0.20% has dropped 11.8%.

/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 18.70
-0.70 -3.61%
Volume: 3.66M
Oct. 5, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.52 billion
Rev. per Employee
$837,729
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 125.62
-0.05 -0.04%
Volume: 2.28M
Oct. 5, 2022 4:00p
P/E Ratio
3.83
Dividend Yield
N/A
Market Cap
$49.16 billion
Rev. per Employee
$8.47M
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 137.19
-0.38 -0.28%
Volume: 508,364
Oct. 5, 2022 4:00p
P/E Ratio
2.62
Dividend Yield
0.00%
Market Cap
$33.39 billion
Rev. per Employee
$7.80M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,783.28
-7.65 -0.20%
Volume: 2.22B
Oct. 5, 2022 5:03p
loading...

Get news alerts on Novavax Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.